14 citations
,
May 2016 in “Therapeutic advances in urology” This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.
9 citations
,
February 2018 in “Journal of Pharmaceutical and Biomedical Analysis” This study validated a highly selective and fast LC–MS/MS method for accurately measuring levels of tadalafil and finasteride in human plasma, adhering to international bioanalytical guidelines.
3 citations
,
July 2022 in “BMC chemistry” This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.
1 citations
,
October 2023 in “Journal of personalized medicine” In this study, researchers investigated genetic variants in pharmacogenes affecting tadalafil and finasteride pharmacokinetics, finding fed volunteers had higher drug exposure than fasting individuals, but genetic variation did not significantly impact pharmacokinetics after correcting for multiple comparisons.
December 2025 in “JURNAL PIJAR MIPA” This study found that a natural hair tonic spray formulated from 15% water pumpkin fruit extract promoted rabbit hair growth to a degree comparable to a synthetic control.
December 2025 in “Molecular Pharmaceutics” In this study, researchers developed a coamorphous form of tadalafil and finasteride, showing improved solubility and dissolution in vitro, with results successfully translated in vivo in rats. They reported reasonable stability, suggesting this form could serve as a therapeutic alternative to the current marketed combination.
December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” In this study, researchers created a coamorphous system combining tadalafil and finasteride that demonstrated improved solubility, dissolution, and stability compared to their physical mixture, offering potential therapeutic advantages for benign prostatic hyperplasia.
January 2025 in “International Journal of Drug Delivery Technology” In this study, researchers developed a reliable HPLC method to simultaneously estimate Finasteride and Tadalafil in marketed formulations, showing precise, linear results with confirmed degradation susceptibility under certain stress conditions.
September 2024 in “International Journal of Applied Pharmaceutics” This study describes a new LC-MS/MS method for analyzing Finasteride and Tadalafil, demonstrating system suitability, linearity, and accuracy in pharmacokinetic studies in rats, aligning with USFDA guidelines.
May 2023 in “Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy” This study developed a synchronized fluorescence spectroscopic approach to quantify finasteride and tadalafil in various forms, achieving high accuracy with %recoveries of about 99.62% and 100.19% respectively, and demonstrated superior environmental friendliness compared to previous methods.
This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.
January 2023 in “RSC Advances” This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
May 2025 in “Cermin Dunia Kedokteran” This study describes Coats disease as a non-hereditary, idiopathic retinopathy characterized by abnormal retinal vascular development, noting common symptoms such as leukokoria and strabismus, and emphasizes the use of imaging techniques to differentiate it from retinoblastoma.
January 2022 in “Drugs of Today” November 2024 in “African Journal of Biomedical Research”
19 citations
,
September 2011 in “Seminars in Cutaneous Medicine and Surgery” This review discusses home-use laser and light skin devices for various dermatological purposes and reports no new clinical findings; the authors highlight the need for dermatologists to evaluate these devices' clinical value.
35 citations
,
May 2020 in “Frontiers in Pharmacology” This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.
20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
5 citations
,
April 2022 in “Egyptian Journal of Chemistry” This study found that a subfraction from Sansevieria trifasciata showed higher hair growth activity than other fractions in tests on rabbits.
4 citations
,
January 2018 in “Research journal of pharmacy and technology” This study found that Wera leaf extract, particularly its n-hexane fraction, significantly stimulated hair growth, suggesting its potential as an antialopecia treatment.
3 citations
,
February 2019 in “Molecular genetics and metabolism” This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.
2 citations
,
November 2019 in “Current Geriatrics Reports” Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.
1 citations
,
December 2023 in “Curēus” This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.
1 citations
,
July 2013 in “JAMA Dermatology” This abstract is a website placeholder and reports no research findings or results; it contains navigation and policy information for JAMA Dermatology.
This study found that PRP injections may safely improve penile curvature and PDQ scores in men with stable-phase Peyronie's Disease, although the curvature reduction observed was not enough to determine long-term clinical significance.
February 2024 in “Urology” This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.
January 2024 in “Jurnal Ilmiah Ibnu Sina (JIIS) Ilmu Farmasi dan Kesehatan” In this study, researchers developed a hair tonic using shallots (Allium cepa L.) and found that its F2 formulation was as effective as the positive control in promoting hair growth on the 21st day and remained stable over 28 weeks of testing.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.